773135-56-1

Basic information

• Product Name: Benzoic acid, 2,3-difluoro-4-methyl-, ethyl ester (9CI)
• Synonyms: Benzoic acid, 2,3-difluoro-4-methyl-, ethyl ester (9CI);2,3-Difluoro-4-methylbenzoic acid ethyl ester;Ethyl 2,3-difluoro-4-methyl-benzoate
• CAS NO: 773135-56-1
• Molecular Formula: C₁₀H₁₀F₂O₂
• Molecular Weight: 200.1820064
• Product Categories: METHYL
• Mol File: 773135-56-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoic acid, 2,3-difluoro-4-methyl-, ethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2,3-difluoro-4-methyl-, ethyl ester (9CI)(773135-56-1)
• EPA Substance Registry System: Benzoic acid, 2,3-difluoro-4-methyl-, ethyl ester (9CI)(773135-56-1)

Safety Data

• Hazardous Substances Data: 773135-56-1(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 261763-37-5 2,3-difluoro-4-methylbenzoic acid 

Downstream Products

• 1436424-66-6 4-((2-(2,5-diazabicyclo[2.2.1]heptan-2-yl)acetamido)methyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2,3-difluorobenzamide 
• 1436424-53-1 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2,3-difluoro-4-((2-(4-(hydroxymethyl)piperidin-1-yl)acetamido)methyl)benzamide 
• 1436423-27-6 (R)-tert-butyl 3-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzylcarbamoyl)thiomorpholine-4-carboxylate 
• 1436423-29-8 (R)-N-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzyl)thiomorpholine-3-carboxamide 
• 1436423-50-5 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2,3-difluoro-4-((2-hydroxyacetamido)methyl)benzamide 
• 1436423-02-7 tert-butyl 4-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzylcarbamoyl)piperidine-1-carboxylate 
• 1449693-12-2 C₂₆H₃₀ClF₅N₄O₃ 

Relevant articles and documents

MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the Mas receptor, and are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune system, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. These diseases and disorders include, for example, vascular disorders, such as: coronary heart disease, atherosclerosis, ischemia, reperfusion injury, angina pectoris, myocardial infarction, the no-reflow phenomenon, hypertension, transient ischemic attack, ischemic colitis, mesenteric ischemia, acute limb ischemia, and skin discoloration caused by reduced blood flow to the skin; and calcium-signaling disorders such as: arrhythmia, tachycardia, bradycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, Wolff-Parkinson-White syndrome, ventricular arrhythmia, ventricular tachycardia, ventricular fibrillation, reperfusion arrhythmia, and reperfusion-induced cardiomyocyte cell death.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.